company background image
GENO

Genovis AB (publ.) OM:GENO Stock Report

Last Price

kr51.40

Market Cap

kr3.4b

7D

-1.9%

1Y

2.0%

Updated

15 Aug, 2022

Data

Company Financials +
GENO fundamental analysis
Snowflake Score
Valuation3/6
Future Growth6/6
Past Performance6/6
Financial Health6/6
Dividends0/6

GENO Stock Overview

Genovis AB (publ.) designs, develops, and sells tools for development of drugs for customers in the pharmaceutical and medical device industries.

Genovis AB (publ.) Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Genovis AB (publ.)
Historical stock prices
Current Share Pricekr51.40
52 Week Highkr90.00
52 Week Lowkr40.25
Beta1.53
1 Month Change7.08%
3 Month Change1.78%
1 Year Change1.98%
3 Year Change110.66%
5 Year Change1,678.55%
Change since IPO-51.96%

Recent News & Updates

Jul 08
If EPS Growth Is Important To You, Genovis AB (publ.) (STO:GENO) Presents An Opportunity

If EPS Growth Is Important To You, Genovis AB (publ.) (STO:GENO) Presents An Opportunity

For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...

Jun 01
Is There An Opportunity With Genovis AB (publ.)'s (STO:GENO) 43% Undervaluation?

Is There An Opportunity With Genovis AB (publ.)'s (STO:GENO) 43% Undervaluation?

How far off is Genovis AB (publ.) ( STO:GENO ) from its intrinsic value? Using the most recent financial data, we'll...

Shareholder Returns

GENOSE Life SciencesSE Market
7D-1.9%5.8%2.3%
1Y2.0%-52.0%-21.8%

Return vs Industry: GENO exceeded the Swedish Life Sciences industry which returned -52% over the past year.

Return vs Market: GENO exceeded the Swedish Market which returned -21.8% over the past year.

Price Volatility

Is GENO's price volatile compared to industry and market?
GENO volatility
GENO Average Weekly Movement7.9%
Life Sciences Industry Average Movement7.9%
Market Average Movement7.2%
10% most volatile stocks in SE Market12.6%
10% least volatile stocks in SE Market4.5%

Stable Share Price: GENO is not significantly more volatile than the rest of Swedish stocks over the past 3 months, typically moving +/- 8% a week.

Volatility Over Time: GENO's weekly volatility (8%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
199936Fredrik Olssonhttps://www.genovis.com

Genovis AB (publ.) designs, develops, and sells tools for development of drugs for customers in the pharmaceutical and medical device industries. The company offers FabALACTICA, a cysteine protease that digests human IgG1; FabRICATOR, an enzyme that primarily digests the hinge region of IgG; and FabRICATOR Z, an enzyme for the digestion of mouse IgG2a and IgG3, as well as for generating a homogenous pool of F(ab')2 and Fc fragments. It also provides FabULOUS (SpeB), an enzyme for the digestion of IgG in the hinge region; and GingisKHAN, a cysteine protease that digests human IgG1 at a specific site above the hinge.

Genovis AB (publ.) Fundamentals Summary

How do Genovis AB (publ.)'s earnings and revenue compare to its market cap?
GENO fundamental statistics
Market Capkr3.39b
Earnings (TTM)kr36.05m
Revenue (TTM)kr116.70m

93.3x

P/E Ratio

28.8x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
GENO income statement (TTM)
Revenuekr116.70m
Cost of Revenuekr14.31m
Gross Profitkr102.39m
Other Expenseskr66.34m
Earningskr36.05m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

Nov 15, 2022

Earnings per share (EPS)0.55
Gross Margin87.74%
Net Profit Margin30.89%
Debt/Equity Ratio0.0%

How did GENO perform over the long term?

See historical performance and comparison